{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:03:14Z","timestamp":1758704594509,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Musculoskeletal manifestations are common extraintestinal manifestations of inflammatory bowel disease. Tofacitinib is a Janus kinase inhibitor approved for treating rheumatoid arthritis and ulcerative colitis. There are limited data on the efficacy of tofacitinib in managing inflammatory bowel disease-associated arthritis. Here we report two patients with ulcerative colitis- and Crohn\u2019s disease-associated arthritis successfully responding to tofacitinib.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Cases<\/jats:title>\n                <jats:p>A 34-year-old Bangladeshi woman presented with lower limb polyarthritis for 7\u00a0years. Six months after the onset of polyarthritis, she developed abdominal pain with rectal bleeding. Colonoscopy and rectal biopsy findings confirmed ulcerative colitis. Ulcerative colitis associated arthritis was diagnosed. Treatment with sulfasalazine, etanercept, adalimumab, infliximab,\u2009and\u2009methotrexate gave no long-lasting remission. Methotrexate with mesalazine gave a partial response, and tofacitinib 5\u00a0mg twice per day was added. Her articular and abdominal symptoms improved within a month, and remission persisted till 24\u00a0months of follow-up, except a short-lasting mild flare at the seventh month. A 52-year-old Bangladeshi man had Crohn\u2019s disease for 5\u00a0years. He presented with a swollen left knee and pain in other joints. Laboratory showed positive HLA-B27. He was intolerant to sulfasalazine and experienced poor response to methotrexate. Due to his inability to afford anti-tumor necrosis factor, tofacitinib was initiated. His arthritis improved within a month, and he remained in remission up to the sixth month.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In a woman with ulcerative colitis associated arthritis, refractory to biologic therapy, both arthritis and colitis improved with tofacitinib. A patient with Crohn\u2019s disease-associated arthritis went into remission with tofacitinib. Tofacitinib may be effective in inflammatory bowel disease-associated arthritis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-03796-2","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T01:02:46Z","timestamp":1677632566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7901-0847","authenticated-orcid":false,"given":"Muhammad Shoaib","family":"Momen Majumder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4154-7283","authenticated-orcid":false,"given":"Syed Atiqul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0399-2669","authenticated-orcid":false,"given":"Johannes J.","family":"Rasker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"issue":"7","key":"3796_CR1","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3390\/nu11071498","volume":"11","author":"AH Keshteli","year":"2019","unstructured":"Keshteli AH, Madsen KL, Dieleman LA. Diet in the pathogenesis and management of ulcerative colitis; a review of randomized controlled dietary interventions. Nutrients. 2019;11(7):1498.","journal-title":"Nutrients"},{"issue":"4","key":"3796_CR2","first-page":"235","volume":"7","author":"JS Levine","year":"2011","unstructured":"Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011;7(4):235.","journal-title":"Gastroenterol Hepatol"},{"key":"3796_CR3","unstructured":"Inman RD. 'Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases.' UpToDate; 2021. https:\/\/www.uptodate.com\/contents\/clinical-manifestations-and-diagnosis-of-arthritis-associated-with-inflammatory-bowel-disease-and-other-gastrointestinal-diseases. Accessed 19 Jan 2022."},{"key":"3796_CR4","unstructured":"Inman RD. 'Treatment of arthritis associated with inflammatory bowel disease.' UpToDate; 2022. https:\/\/www.uptodate.com\/contents\/treatment-of-arthritis-associated-with-inflammatory-bowel-disease. Accessed 2 Feb 2022."},{"key":"3796_CR5","unstructured":"FDA approves new treatment for moderately to severely active ulcerative colitis [press release]. 2018."},{"issue":"1","key":"3796_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000502816","volume":"101","author":"P Juillerat","year":"2020","unstructured":"Juillerat P, Manz M, Sauter B, Zeitz J, Vavricka SR. Therapies in inflammatory bowel disease patients with extraintestinal manifestations. Digestion. 2020;101(1):83\u201397.","journal-title":"Digestion"},{"issue":"3","key":"3796_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.crohns.2009.11.005","volume":"4","author":"LK Brakenhoff","year":"2010","unstructured":"Brakenhoff LK, van der Heijde DM, Hommes DW, Huizinga TW, Fidder HH. The joint\u2013gut axis in inflammatory bowel diseases. J Crohns Colitis. 2010;4(3):257\u201368.","journal-title":"J Crohns Colitis"},{"issue":"12","key":"3796_CR8","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/art.41906","volume":"73","author":"C Liu","year":"2021","unstructured":"Liu C, Kieltyka J, Fleischmann R, Gadina M, O\u2019Shea JJ. A decade of JAK inhibitors: what have we learned and what may be the future? Arthritis Rheumatol. 2021;73(12):2166\u201378.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"3796_CR9","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez J-B, Dowty ME, et\u00a0al. The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318\u201328.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"3796_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/ecco-jcc\/jjx158","volume":"12","author":"SR Vavricka","year":"2018","unstructured":"Vavricka SR, Galv\u00e1n JA, Dawson H, Soltermann A, Biedermann L, Scharl M, et\u00a0al. Expression patterns of TNF\u03b1, MAdCAM1, and STAT3 in intestinal and skin manifestations of inflammatory bowel disease. J Crohns Colitis. 2018;12(3):347\u201354.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3796_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N, Colombel J-F. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1): e135.","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"3796_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384\u2013413.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"3796_CR13","doi-asserted-by":"publisher","first-page":"e00226","DOI":"10.14309\/crj.0000000000000226","volume":"6","author":"W Wang","year":"2019","unstructured":"Wang W, Cleveland NK, Ollech J, Rubin DT. Use of tofacitinib for the treatment of arthritis associated with ulcerative colitis. ACG Case Rep J. 2019;6(9):e00226.","journal-title":"ACG Case Rep J."},{"issue":"4","key":"3796_CR14","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","volume":"17","author":"C Le Berre","year":"2019","unstructured":"Le Berre C, Loeuille D, Peyrin-Biroulet L. Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy. Clin Gastroenterol Hepatol. 2019;17(4):794\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3796_CR15","doi-asserted-by":"publisher","first-page":"175628482110057","DOI":"10.1177\/17562848211005708","volume":"14","author":"DT Rubin","year":"2021","unstructured":"Rubin DT, Reinisch W, Greuter T, Kotze PG, Pinheiro M, Mundayat R, et\u00a0al. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Ther Adv Gastroenterol. 2021;14:17562848211005708.","journal-title":"Ther Adv Gastroenterol"},{"issue":"Supplement_2","key":"3796_CR16","doi-asserted-by":"publisher","first-page":"S746","DOI":"10.1093\/ecco-jcc\/jjz186","volume":"14","author":"G Rogler","year":"2020","unstructured":"Rogler G. Efficacy of JAK inhibitors in Crohn\u2019s disease. J Crohn\u2019s Colitis. 2020;14(Supplement_2):S746\u201354.","journal-title":"J Crohn\u2019s Colitis."},{"key":"3796_CR17","doi-asserted-by":"publisher","first-page":"S1148","DOI":"10.14309\/01.ajg.0000597736.21235.a9","volume":"114","author":"B Gordon","year":"2019","unstructured":"Gordon B, Longman R, Scherl EJ. 2051 Tofacitinib improves refractory Crohn\u2019s disease-associated arthritis. Am J Gastroenterol. 2019;114:S1148.","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03796-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-03796-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03796-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T01:02:54Z","timestamp":1677632574000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-03796-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3796"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-03796-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"3 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following the basic principles of the Declaration of Helsinki. This case series was written after obtaining informed consent from the patients for publication. The purpose of the research was completely explained to the patients, and they were assured that their information will be kept confidential by the researchers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}